CN1326520C - A pharmaceutical composition and application thereof in preparation of medicine for preventing or treating cerebrovascular and cardiovascular disease - Google Patents
A pharmaceutical composition and application thereof in preparation of medicine for preventing or treating cerebrovascular and cardiovascular disease Download PDFInfo
- Publication number
- CN1326520C CN1326520C CNB2004100591760A CN200410059176A CN1326520C CN 1326520 C CN1326520 C CN 1326520C CN B2004100591760 A CNB2004100591760 A CN B2004100591760A CN 200410059176 A CN200410059176 A CN 200410059176A CN 1326520 C CN1326520 C CN 1326520C
- Authority
- CN
- China
- Prior art keywords
- salvianolic acid
- total salvianolic
- carthamus yellow
- group
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 10
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims description 35
- 235000017276 Salvia Nutrition 0.000 claims abstract description 7
- 241001072909 Salvia Species 0.000 claims abstract 5
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 claims description 78
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 claims description 77
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 claims description 73
- 229930183842 salvianolic acid Natural products 0.000 claims description 73
- 241000208809 Carthamus Species 0.000 claims description 72
- 239000000203 mixture Substances 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000011347 resin Substances 0.000 claims description 16
- 229920005989 resin Polymers 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000008367 deionised water Substances 0.000 claims description 13
- 229910021641 deionized water Inorganic materials 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 10
- 239000003480 eluent Substances 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 239000003463 adsorbent Substances 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 8
- 238000005325 percolation Methods 0.000 claims description 7
- 241000628997 Flos Species 0.000 claims description 5
- 208000031225 myocardial ischemia Diseases 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000004952 Polyamide Substances 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- IAVUBSCVWHLRGE-UXEKTNMQSA-N (6e)-2,5-dihydroxy-6-[(e)-1-hydroxy-3-(4-hydroxyphenyl)prop-2-enylidene]-2,4-bis[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]cyclohex-4-ene-1,3-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C(C(C(O)([C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C1=O)=O)=C(O)\C1=C(/O)\C=C\C1=CC=C(O)C=C1 IAVUBSCVWHLRGE-UXEKTNMQSA-N 0.000 claims description 2
- 230000006931 brain damage Effects 0.000 claims description 2
- 231100000874 brain damage Toxicity 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- ZZMASNSDVDSYKO-UHFFFAOYSA-N hydroxysafflor yellow A Natural products OCC1OC(C(O)C(O)C1O)C2=C(O)C(O)(C3OC(CO)C(O)C(O)C3O)C(=O)C(=C2O)C(=O)C=Cc4ccc(O)cc4 ZZMASNSDVDSYKO-UHFFFAOYSA-N 0.000 claims description 2
- 239000012567 medical material Substances 0.000 claims description 2
- 150000007965 phenolic acids Chemical class 0.000 abstract 3
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 abstract 3
- 239000001052 yellow pigment Substances 0.000 abstract 3
- MZZSDCJQCLYLLL-UHFFFAOYSA-N Secalonsaeure A Natural products COC(=O)C12OC3C(CC1=C(O)CC(C)C2O)C(=CC=C3c4ccc(O)c5C(=O)C6=C(O)CC(C)C(O)C6(Oc45)C(=O)OC)O MZZSDCJQCLYLLL-UHFFFAOYSA-N 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 28
- 239000000843 powder Substances 0.000 description 16
- 230000000302 ischemic effect Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 206010061216 Infarction Diseases 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000007574 infarction Effects 0.000 description 7
- 201000006474 Brain Ischemia Diseases 0.000 description 6
- 206010008120 Cerebral ischaemia Diseases 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 206010008118 cerebral infarction Diseases 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 206010000117 Abnormal behaviour Diseases 0.000 description 5
- -1 Hydroxyl carthamin Chemical compound 0.000 description 5
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 210000000269 carotid artery external Anatomy 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 4
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 240000007164 Salvia officinalis Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003194 forelimb Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000594182 Sarcophaga sigma Species 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 239000009874 shenqi Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a pharmaceutical composition composed of safflower yellow pigment and total salvia phenolic acid, wherein the safflower yellow pigment comprises hydroxyl safflower yellow pigment A whose content is larger than or equal to 50%; the total salvia phenolic acid comprises salvia phenolic acid B or a salt whose content is larger than or equal to 50%. The present invention also provides the application of the pharmaceutical composition for preparing medicine for treating or preventing cardiovascular diseases and cerebrovascular diseases.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition of forming by Carthamus yellow and total salvianolic acid, also relate to its application in the medicine of preparation treatment or prevention cardiovascular and cerebrovascular disease.
Background technology
Carthamus yellow is the effective ingredient that extracts from Flos Carthami, have multiple pharmacology's effects such as coronary artery dilator, blood pressure lowering, antithrombotic, anoxia enduring, immunosuppressant, see [the modern study general introduction of Carthamus yellow, Wang Huiling, China's Chinese medicine science and technology, 1998 the 5th the 5th phases of volume].
Total salvianolic acid is the water soluble ingredient of Radix Salviae Miltiorrhizae; it has antiplatelet aggregation, antithrombotic formation, microcirculation improvement and anti-oxidative damage effect and multipath performance myocardium protecting action; see [present Research of red sage formulation and what time thinking deeply to exploitation; Zhang Jun etc.; Chinese herbal medicine, the 32nd the 10th phase of volume of calendar year 2001].
The inventor is by a large amount of experimentatioies, a kind of pharmaceutical composition and application of being made up of Carthamus yellow, total salvianolic acid in the medicine of preparation treatment or prevention cardiovascular and cerebrovascular disease thereof is provided, and this pharmaceutical composition has synergism when being used for cardiovascular and cerebrovascular disease.
Summary of the invention
The invention provides a kind of pharmaceutical composition of being made up of Carthamus yellow, total salvianolic acid, wherein the weight ratio of Carthamus yellow and total salvianolic acid is 1: 19～19: 1, is preferably 1: 4～4: 1, more preferably 1: 3; Hydroxyl carthamin yellow A-containing in the Carthamus yellow 〉=50% contains salvianolic acid B 〉=50% in the total salvianolic acid, salvianolic acid B can also exist with the form of slaine, is preferably magnesium salt.
The invention provides the Carthamus yellow and the preparation method that contains the total salvianolic acid of salvianolic acid B 〉=50% of hydroxyl carthamin yellow A-containing 〉=50%.
The invention provides the application of pharmaceutical composition in the medicine of preparation treatment or prevention cardiovascular and cerebrovascular disease of forming by Carthamus yellow, total salvianolic acid.
The invention provides the application of this pharmaceutical composition in the medicine of preparation treatment or prevention of brain damage.
The invention provides the application of this pharmaceutical composition in the medicine of preparation treatment or prevention myocardial ischemia.
Pharmaceutical composition provided by the invention can be according to the preparation needs, add corresponding adjuvant, exist with tablet, pill, granule, capsule, suspension, solution, syrup, injection, cream, ointment, spray, chewing agent or patch form, be preferably freeze-dried powder.Various dosage form provided by the invention all can adopt the pharmacy conventional method to be prepared from.
Pharmaceutical composition provided by the invention is when being used for cardiovascular and cerebrovascular disease, and its using dosage scope is 35mg-1000mg, is preferably 50mg-400mg.
Pharmaceutical composition provided by the invention, when existing with dosage form, its content of effective is 35-400mg.
Carthamus yellow of the present invention is that extraction separation obtains from Flos Carthami, preferably adopts water extracting method, with macroporous adsorbent resin column chromatography method and the combination of polyamide absorption method, obtains Carthamus yellow.Total salvianolic acid of the present invention is that extraction separation obtains from Radix Salviae Miltiorrhizae, preferably adopts water extracting method, with macroporous adsorbent resin column chromatography method exquisiteness, obtains total salvianolic acid.
The inventor has carried out following test and has confirmed the effect in the medicine of preparation treatment or prevention cardiovascular and cerebrovascular disease of the pharmaceutical composition be made up of Carthamus yellow and total salvianolic acid, has synergism.
The specific embodiment;
Preparation example 1: the preparation of Carthamus yellow, total salvianolic acid
Get flos carthami 5kg, 30 times of water gaging percolation filter, with absorption with macroporous adsorbent resin (volume ratio of extracting solution and resin 3: 1),, continue then with 5 column volumes of deionized water eluting with 2 column volumes of deionized water eluting, collect eluent, the absorption of reuse polyamide, elder generation is washed till colourless with deionized water, use 95% ethanol elution of meta-alkalescence then, collect eluent, concentrate on the rotary evaporator and remove ethanol, lyophilization obtains Carthamus yellow, and wherein hydroxyl carthamin yellow A-containing 75.8%.
Get red rooted salvia 5kg, pulverize, 30 times of amount sour water percolation extract, filter, adsorb (volume ratio of extracting solution and resin 3: 1) with macroporous adsorbent resin, with deionized water eluting 3-5 column volume, 5 column volumes of the alcoholic solution eluting of reuse 30%, collect eluent, the adjusting pH value is 2-5, concentrates ethanol, lyophilizing, get total salvianolic acid, wherein contain salvianolic acid B 80.4%.
Preparation example 2: the preparation of Carthamus yellow, total salvianolic acid
Get flos carthami 5kg, 30 times of water gaging percolation filter, with absorption with macroporous adsorbent resin (volume ratio of extracting solution and resin 3: 1), with 2 column volumes of deionized water eluting, continue then to collect eluent with 5 column volumes of deionized water eluting, concentrating the back is immobile phase with the polydextran gel, separate with the deionized water eluting, collect the S-A Hydroxysafflor yellow A composition, concentrate on the rotary evaporator, lyophilization obtains Carthamus yellow, and wherein hydroxyl carthamin yellow A-containing 77.5%.
Get red rooted salvia and pulverize, 15 times of amount 60% acetone carry out percolation, collect percolate, concentrate, do not distinguish the flavor of to there being acetone, after water dilutes, carry out absorption with macroporous adsorbent resin (medical material amount and amount of resin 1: 1), with deionized water eluting 3-5 column volume, 5 column volumes of the alcoholic solution eluting of reuse 30%, collect eluent, concentrate ethanol, lyophilizing gets total salvianolic acid, wherein contains salvianolic acid B magnesium salt 72.8%.
Preparation example 3: the freeze-dried powder that preparation is made up of Carthamus yellow and total salvianolic acid
Under cleaning condition, get Carthamus yellow 190g, total salvianolic acid 10g, be dissolved in 1000ml water for injection, add 100g mannitol, stirring and dissolving, ultrafiltration obtains apyrogenic clear liquor, press the lyophilizing of freeze-dried powder technology, make the freeze-dried powder that contains Carthamus yellow 190mg, total salvianolic acid 10mg.
Preparation example 4: the freeze-dried powder that preparation is made up of Carthamus yellow and total salvianolic acid
Under cleaning condition, get Carthamus yellow 10g, total salvianolic acid 190g, be dissolved in 1000ml water for injection, stirring and dissolving, ultrafiltration obtains apyrogenic clear liquor, press the lyophilizing of freeze-dried powder technology, make the freeze-dried powder that contains Carthamus yellow 10mg, total salvianolic acid 190mg.
Preparation example 5: the freeze-dried powder that preparation is made up of Carthamus yellow and total salvianolic acid
Under cleaning condition, get Carthamus yellow 20g, total salvianolic acid 80g, be dissolved in 1000ml water for injection, add the 100g low molecular dextran, stirring and dissolving, ultrafiltration obtains apyrogenic clear liquor, press the lyophilizing of freeze-dried powder technology, make the freeze-dried powder that contains Carthamus yellow 20mg, total salvianolic acid 80mg.
Preparation example 6: the freeze-dried powder that preparation is made up of Carthamus yellow and total salvianolic acid
Under cleaning condition, get Carthamus yellow 80g, total salvianolic acid 20g, be dissolved in 1000ml water for injection, add the 100g low molecular dextran, stirring and dissolving, ultrafiltration obtains apyrogenic clear liquor, press the lyophilizing of freeze-dried powder technology, make the freeze-dried powder that contains Carthamus yellow 80mg, total salvianolic acid 20mg.
Preparation example 7: the freeze-dried powder that preparation is made up of Carthamus yellow and total salvianolic acid
Under cleaning condition, get Carthamus yellow 25g, total salvianolic acid 75g, be dissolved in 1000ml water for injection, stirring and dissolving, ultrafiltration obtains apyrogenic clear liquor, press the lyophilizing of freeze-dried powder technology, make the freeze-dried powder that contains Carthamus yellow 25mg, total salvianolic acid 75mg.
Test example 1: the influence that various dose Carthamus yellow, total salvianolic acid, compositions are damaged the rat local cerebral ischemia
(1) material:
Carthamus yellow, total salvianolic acid, compositions: by preparation example 1 preparation.
Red tetrazolium: U.S. Sigma company product, face with preceding and be made into 4% solution with normal saline.
Laboratory animal: regular grade SD rat, male, body weight 280g-350g, natural drug Engineering Technical Research Centre zoopery center, Shandong Province provides.The quality certification number: No. 200106005, Shandong kinoplaszm word.
(2) method and result:
Animal is divided into sham operated rats (normal saline) at random, model control group (normal saline), nimodipine group (Nim, 1.0mg/kg), Carthamus yellow small dose group (1.5mg/kg), dosage group (3.5mg/kg) in the Carthamus yellow, the heavy dose of group of Carthamus yellow (45mg/kg), total salvianolic acid small dose group (2mg/kg), dosage group (3.5mg/kg) in the total salvianolic acid, the heavy dose of group of total salvianolic acid (60mg/kg), compositions low dose [Carthamus yellow (1.5mg/kg)+total salvianolic acid (2mg/kg)], every group of 1O of compositions heavy dose [Carthamus yellow (45mg/kg)+total salvianolic acid (60mg/kg)] is only.After the fasting 12 hours, and chloral hydrate (350mg/kg, i.p.) anesthesia separates right carotid, and folder closes in the neck, common carotid artery, external carotid artery proximal part and distal end ligation, cut off the centre.The external carotid artery free-end is pulled to internal carotid artery in alignment, bolt line (selecting diameter 0.24mm nylon wire for use, length 5.0cm) is inserted into intracranial by external carotid artery, stop when meeting slight resistance, insertion depth is about 2cm.Ligation external carotid artery opening, and open the common carotid artery bulldog clamp, the disinfection and stitching wound causes right side middle cerebral artery ischemia model; Sham operated rats is only carried out the separation (above experiment is all carried out at 23 ℃～25 ℃) of right carotid, internal carotid artery, external carotid artery.Each treated animal intravenous injection relative medicine of postoperative.Press document [Liu Xiaoguang, Xu Lina, a kind of rat brain medium-sized artery model that can estimate thrombolytic and anti-thrombolytic after 24 hours, Acta Pharmaceutica Sinica, 1995,30:662] described method and standard is observed and the behavior disorder of record rat: (A) carry the Mus tail and observe forelimb flexing situation, stretch to ground as two forelimb symmetries, count 0 fen, the wrist flexing occurs as operation offside forelimb and count 1 fen, the elbow flexing is counted 2 fens, the shoulder inward turning is counted 3 fens, existing wrist flexing and/or elbow flexing have shoulder inward turning person again, count 4 fens.(B) animal is placed on the plane earth, push away both shoulders respectively, check resistance to side shifting.As bilateral resistance equity and strong, count 0 fen, as resistance descender when the operation offside promotes, according to decline degree difference be divided into gently, in, weigh three degree, count 1,2 and 3 fen respectively.(C) the two forelimbs of animal are put on the wire netting, observed the muscular tension of two forelimbs.Two muscle of anterior limb tension force equities and strong person count 0 fen.Count 1,2 and 3 fen according to operation offside muscular tension decline degree difference equally.(D) animal has ceaselessly to a side person of turn-taking, and counts 1 fen.According to the standard scoring, full marks are 11 minutes, and mark is high more, and expression animal behavior obstacle is serious more.
Put to death rat behind the behavior scoring, get brain, remove olfactory bulb, cerebellum and low brain stem, crownly be cut into 5, the brain sheet takes on a red color after normal structure is dyed with red tetrazolium (TTC) dyeing, and blocking tissue is white in color, taking a picture in dyeing back, asks the infarct size ratio with Chinese Aero-Space university pathological image analysis software.Data are used
Expression is carried out statistical procedures with F check between group.
The result is as shown in table 1, and ischemia is after 24 hours, and the model group rat shows tangible behavior disorder, and tangible kitchen range shape ischemic region also appears in rat cerebral tissue, reaches about 25% of full brain.
1.5mg/kg Carthamus yellow and 2mg/kg total salvianolic acid group are failed to improve the rat behavior obstacle, are reduced ischemic areas; 3.5mg/kg Carthamus yellow and 3.5mg/kg total salvianolic acid group have all been improved the rat behavior obstacle to a certain extent, have been reduced ischemic areas.
Compositions small dose group [Carthamus yellow (1.5mg/kg)+total salvianolic acid (2mg/kg)] is improved the rat behavior obstacle very significantly, is reduced ischemic areas, compare p＜0.01 with model group, and significant difference (P＜0.05) is more also arranged with 3.5mg/kg Carthamus yellow, 3.5mg/kg total salvianolic acid.Carthamus yellow and total salvianolic acid have synergism in the prompting compositions.
Compositions heavy dose [Carthamus yellow (45mg/kg)+total salvianolic acid (60mg/kg)] is improved the rat behavior obstacle extremely significantly, is reduced ischemic areas, compares P＜0.001 with model group.
The influence that table 1 Carthamus yellow, total salvianolic acid, compositions are damaged the rat local cerebral ischemia
| Group | Behavior disorder | Ischemic areas (%) |
| The heavy dose of group of the heavy dose of group of dosage group total salvianolic acid composition small dose group composition in the heavy dose of group of the dosage group carthamin yellow total salvianolic acid small dose group total salvianolic acid in the sham-operation group model control group Nim group carthamin yellow small dose group carthamin yellow | 0 11.50±1.31 7.15±2.66 **10.22±3.16 8.80±1.07 *6.86±3.17 **10.03±3.58 8.79±2.42 *6.58±1.96 **6.67±2.35 **#△ 5.03±1.55 *** | 0 25.41±4.22 17.33±5.68 **22.38±8.95 19.23±2.45 *12.91±4.32 **23.14±6.27 19.56±3.75 *12.37±4.48 **13.34±7.56 **#△ 10.22±2.56 *** |
Compare with model control group
*P＜0.05,
*P＜0.01,
* *P＜0.001.
Compare #P＜0.05 with dosage group in the Carthamus yellow
Compare with dosage group in the total salvianolic acid
△P＜0.05
Test example 2: different proportioning pharmaceutical compositions are to the influence of rat local cerebral ischemia damage
Carthamus yellow, total salvianolic acid, compositions: by preparation example 2 preparations.
Red tetrazolium: U.S. Sigma company product, face with preceding and be made into 4% solution with normal saline.
Laboratory animal: regular grade SD rat, male, body weight 280g-350g, natural drug Engineering Technical Research Centre zoopery center, Shandong Province provides.The quality certification number: No. 200106005, Shandong kinoplaszm word.
(2) method and result:
Animal is divided into sham operated rats (normal saline) at random, model control group (normal saline), compositions A[Carthamus yellow (10mg/kg)+total salvianolic acid (0mg/kg)], compositions B[Carthamus yellow (9.5mg/kg)+total salvianolic acid (0.5mg/kg)], compositions C[Carthamus yellow (8mg/kg)+total salvianolic acid (2mg/kg)], compositions D[Carthamus yellow (5mg/kg)+total salvianolic acid (5mg/kg)], compositions E[Carthamus yellow (2mg/kg)+total salvianolic acid (8mg/kg)], composition F [Carthamus yellow (0.5mg/kg)+total salvianolic acid (9.5mg/kg)], compositions G[Carthamus yellow (0mg/kg)+total salvianolic acid (10mg/kg)] 10 every group.Make rat local cerebral ischemia model and carry out neural behavior scoring, the dyeing of brain sheet by method shown in the experimental example 1.
Data are used
Expression is carried out statistical procedures with F check between group.
The result is as shown in table 2, and ischemia is after 24 hours, and the model group rat shows tangible behavior disorder, and tangible kitchen range shape ischemic region also appears in rat cerebral tissue, reaches about 25% of full brain.The pharmaceutical composition (10mg/kg) of different proportionings all has significant protective effect (P＜0.05 or P＜0.01) to rat cerebral ischemia.
The different proportioning pharmaceutical compositions of table 2 are to the influence of rat local cerebral ischemia damage
| Group | Behavior disorder | Ischemic areas (%) |
| Sham-operation group model control group composition A composition B composition C composition D composition E composition F composition G | 0 10.6±1.1 9.1±1.2 * 8.4±1.1 ** 7.0±0.8 **# △ 7.2±0.7 **# △ 7.1±0.9 **# △ 8.5±0.8 * 8.9±0.7 * | 0 25.6±4.5 22.9±2.1 * 22.5±2.1 * 18.2±1.8 **# △ 20.1±1.4 **# △ 21.2±1.3 **# △ 22.3±1.6 * 22.6±1.1 * |
Compare with model control group
*P＜0.05,
*P＜0.01.
Compositions A group is #P＜0.05 relatively
Compositions G organizes relatively
△P＜0.05
Test example 3: Carthamus yellow, total salvianolic acid, compositions are to the influence of rat heart muscle ischemic injuries
(1) material:
Carthamus yellow, total salvianolic acid, compositions: by preparation example 2 preparations.
Painstaking effort pellet (compound Salviae Miltiorrhizae) injection: Guizhou Shenqi Pharmaceutical Co., Ltd.
Chlorination nitro blue tetrazolium (N-BT) is provided by Military Medical Science Institute medical supply station.
Laboratory animal: regular grade Wistar rat, male, body weight 280g-350g, natural drug Engineering Technical Research Centre zoopery center, Shandong Province provides.The quality certification number: No. 200106005, Shandong kinoplaszm word.
(2) method and result:
Animal is divided into sham operated rats (normal saline) at random, model control group (normal saline), FUFANG DANSHEN ZHUSHEYE group (DS, 10mg/kg), Carthamus yellow small dose group (1.5mg/kg), dosage group (3.5mg/kg) in the Carthamus yellow, the heavy dose of group of Carthamus yellow (45mg/kg), total salvianolic acid small dose group (2mg/kg), dosage group (3.5mg/kg) in the total salvianolic acid, the heavy dose of group of total salvianolic acid (60mg/kg), compositions low dose [Carthamus yellow (1.5mg/kg)+total salvianolic acid (2mg/kg)], 10 every group of compositions heavy doses [Carthamus yellow (45mg/kg)+total salvianolic acid (60mg/kg)].After the fasting 12 hours, limbs II lead electrocardiogram is surveyed in ip urethane (1.2g/kg) anesthesia.Cut off left front fur, iodine tincture and alcohol disinfecting, along left border of sternum 1cm place, cut off thoracic wall muscle and two ribs, open the thoracic cavity rapidly, expose heart, the ligation left coronary artery is put back to heart immediately between arterial cone and left auricle, squeezes the thoracic cavity air, use the mosquito forceps closed-chest, cause Model Rats with Acute Myocardial Ischemia.Each treated animal intravenous injection relative medicine of postoperative.1.5h, 3h electrocardiogram before the record administration and after the administration take out heart behind the 6h, after cleaning with cold saline, and-20 ℃ of refrigerator freeze overnight.Next day, refrigerated heart is cut into 5 by ligation place to apex uniform thickness, immerse in the freshly prepared 0.5%NBT phosphate buffer (pH 7.4).37 ℃ of water-bath jolting 10～15min.Blot the dyeing liquor of slice surface with filter paper, separate the coloured portions and the part of being unstained, weigh the compute infarct size.Infarct size (%)=infarction part weight/(non-infarction part weight+infarction part weight) * 100%.
The result is as shown in table 3, and myocardial ischemia is after 6 hours, and tangible kitchen range shape ischemic region appears in the model group rat heart muscle, reaches about 25%.1.5mg/kg Carthamus yellow and 2mg/kg total salvianolic acid group are failed to improve the rat electrocardio, are reduced ischemic areas; 3.5mg/kg Carthamus yellow and 3.5mg/kg total salvianolic acid group all reduce rising, the minimizing ischemic areas of the limb lead electrocardiogram J point that is caused by myocardial ischemia to a certain extent; Compositions small dose group [Carthamus yellow (1.5mg/kg)+total salvianolic acid (2mg/kg)] reduces rising, the minimizing ischemic areas of limb lead electrocardiogram J point very significantly, compare P＜0.01 with model group, and significant difference (P＜0.05) is more also arranged with 3.5mg/kg Carthamus yellow, 3.5mg/kg total salvianolic acid; Compositions heavy dose [Carthamus yellow (45mg/kg) total salvianolic acid (60mg/kg)] reduces rising, the minimizing ischemic areas of limb lead electrocardiogram J point extremely significantly, compares P＜0.001 with model group.
Table 3 Carthamus yellow, total salvianolic acid, compositions are to the influence of rat heart muscle ischemic injuries
| Grouping | Infarct size (%) | The J point raises (10 * mv) | ||
| Normally | 1.5h | 3h | ||
| The heavy dose of group of the heavy dose of group of dosage group total salvianolic acid composition small dose group composition in the heavy dose of group of the dosage group carthamin yellow total salvianolic acid small dose group total salvianolic acid in the model control group danshen injections group carthamin yellow small dose group carthamin yellow | 25.6±4.3 17.8±6.2 *22.5±8.5 19.4±3.5 *12.8±4.5 **23.3±6.4 19.7±3.5 *12.6±4.5 **13.6±7.8 **#△ 10.5±2.7 *** | 0.8±0.6 0.8±0.6 0.7±0.6 0.7±0.5 0.7±0.7 0.8±0.7 0.7±0.6 0.8±0.6 0.8±0.5 0.7±0.6 | 6.7±2.3 6.0±1.5 *6.5±1.3 5.8±1.4 *5.0±1.6 **6.4±1.5 5.7±1.8 *4.9±2.1 **4.7±1.6 **#△ 4.3±1.7 *** | 6.1±1.4 5.1±1.3 *5.8±1.9 5.2±1.8 *4.3±2.0 **5.7±2.1 5.1±1.7 *4.1±1.8 **4.0±1.6 **#△ 3.7±1.9 *** |
Compare with model control group
*P＜0.05,
*P＜0.01,
* *P＜0.001.
Compare #P＜0.05 with dosage group in the Carthamus yellow
Compare △ P＜0.05 with dosage group in the total salvianolic acid
Claims (6)
1. a pharmaceutical composition is made up of Carthamus yellow and total salvianolic acid, and its weight ratio is 1: 19～19: 1, and wherein Carthamus yellow adopts following method preparation:
(1) get an amount of flos carthami and add 30 times of water percolation, filter, absorption with macroporous adsorbent resin (extracting solution and resin volume ratio 3: 1) with 2 column volumes of deionized water eluting, continues to collect eluent with 5 column volumes of deionized water eluting;
(2) eluent is adsorbed with polyamide, elder generation is washed till colourless with deionized water, use 95% ethanol elution then, collects eluent, concentrates and removes alcohol, and lyophilization promptly; Or concentrate eluent back to be immobile phase with the polydextran gel, to separate, collect the S-A Hydroxysafflor yellow A composition that concentrate on the rotary evaporator, lyophilization promptly with the deionized water eluting;
Total salvianolic acid adopts following method preparation:
(1) getting an amount of red rooted salvia pulverizes, 30 times of amount sour water percolation extract, filter, with absorption with macroporous adsorbent resin (extracting solution and resin volume ratio 3: 1), or get an amount of red rooted salvia and pulverize, 15 times of amount 60% acetone carry out percolation, collect percolate, concentrate,, carry out absorption with macroporous adsorbent resin (medical material amount and amount of resin 1: 1) behind the dilute with water to there not being the acetone flavor;
(2) with deionized water eluting 3-5 column volume, 5 column volumes of the alcoholic solution eluting of reuse 30% are collected eluent, concentrate ethanol, and lyophilizing promptly.
2. pharmaceutical composition according to claim 1, the weight ratio of Carthamus yellow and total salvianolic acid are 1: 4～4: 1.
3. pharmaceutical composition according to claim 2, the weight ratio of Carthamus yellow and total salvianolic acid are 1: 3.
4. the application of the arbitrary described compositions of claim 1-3 in the medicine of preparation treatment or prevention cardiovascular and cerebrovascular disease.
5. application according to claim 4, the application of said composition in the medicine of preparation treatment or prevention of brain damage.
6. application according to claim 4, the application of said composition in the medicine of preparation treatment or prevention myocardial ischemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100591760A CN1326520C (en) | 2003-08-28 | 2004-08-17 | A pharmaceutical composition and application thereof in preparation of medicine for preventing or treating cerebrovascular and cardiovascular disease |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN03155283 | 2003-08-28 | ||
| CN03155283.8 | 2003-08-28 | ||
| CNB2004100591760A CN1326520C (en) | 2003-08-28 | 2004-08-17 | A pharmaceutical composition and application thereof in preparation of medicine for preventing or treating cerebrovascular and cardiovascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1736375A CN1736375A (en) | 2006-02-22 |
| CN1326520C true CN1326520C (en) | 2007-07-18 |
Family
ID=36079449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100591760A Expired - Fee Related CN1326520C (en) | 2003-08-28 | 2004-08-17 | A pharmaceutical composition and application thereof in preparation of medicine for preventing or treating cerebrovascular and cardiovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1326520C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104997767A (en) * | 2014-04-25 | 2015-10-28 | 西安世纪盛康药业有限公司 | Pharmaceutical composition containing salvianolic acid B and pharmaceutical application thereof |
| CN105943606B (en) * | 2016-07-21 | 2020-01-21 | 陕西中医药大学 | A pharmaceutical composition for treating cerebral ischemia and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1418678A (en) * | 2002-11-27 | 2003-05-21 | 于文勇 | Medicine compositions for treating cardiovascular cranialvascular disease, and its prepn. method |
| CN1626227A (en) * | 2004-08-16 | 2005-06-15 | 张正生 | Freeze-dried powder and injection preparation of red sage root and safflower, and preparation method |
-
2004
- 2004-08-17 CN CNB2004100591760A patent/CN1326520C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1418678A (en) * | 2002-11-27 | 2003-05-21 | 于文勇 | Medicine compositions for treating cardiovascular cranialvascular disease, and its prepn. method |
| CN1626227A (en) * | 2004-08-16 | 2005-06-15 | 张正生 | Freeze-dried powder and injection preparation of red sage root and safflower, and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1736375A (en) | 2006-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1726966B (en) | Preparation of oral disintegration tablet in use for treating disease of apoplexy and obstruction of qi in the chest | |
| CN100482218C (en) | Application of Danshensu in preparation of medicine for treating cerebrovascular diseases | |
| CN101342274B (en) | Curculigo orchioides extract, preparation method and uses thereof | |
| CN101596182A (en) | Contain pharmaceutical composition, its preparation method, the purposes of salviol acid A and contain the lyophilized injectable powder and the aqueous injection of said composition | |
| CN106344648B (en) | Thymus plant, extract and application thereof | |
| CN1326520C (en) | A pharmaceutical composition and application thereof in preparation of medicine for preventing or treating cerebrovascular and cardiovascular disease | |
| CN101675934B (en) | New use of saponins X of dipsacus asperoides | |
| CN101677989A (en) | A drug composition for treatment and prevention of ischemic stroke and its preparation methods | |
| CN100577184C (en) | Medicine composition and use thereof | |
| CN101919868B (en) | Application of forsythoside B | |
| CN100551372C (en) | A kind of pharmaceutical composition and the application in the medicine of preparation treatment or prevention cardiovascular and cerebrovascular disease thereof | |
| CN103356731B (en) | Pharmaceutical composition containing Cortex Eucommiae extract and Radix Notoginseng total arasaponins and application thereof | |
| CN103830220A (en) | Pharmaceutical composition, and applications thereof in preparation of medicines used for treating cardiovascular and cerebrovascular diseases | |
| CN1626075A (en) | Combination of medication and application of preparing medication for treating or preventing cardiovascular and cerebrovascular diseases | |
| CN103110734B (en) | Traditional Chinese medicine composition for treating gynecologic inflammation and preparation method thereof | |
| CN1911219B (en) | Medicine composition, and its application | |
| CN1868507B (en) | Medicine composition, preparation method and application thereof | |
| CN1732964A (en) | Pharmaceutical composition, its preparation process and usage | |
| CN101485671B (en) | Novel medicinal use of 8-O-acetyl shanzhiside methylester | |
| CN100486578C (en) | Medicine composition and its application in preparation of medicine for treating or preventing cardiovascular and cerebrovascular diseases | |
| CN1331473C (en) | Application of 20(S)-ginsenoside-Rg#[3] in the preparing process of medicine for treating or preventing cardiovascular and cerebrovascular disease | |
| CN106692289B (en) | Medical application of barbat skullcap alcohol extract | |
| CN1868508B (en) | Medicine composition, application of the same for preparing medicine to treat and prevent cardiovascular and cerebrovascular disease | |
| CN109419840A (en) | The new application of honeysuckle | |
| Rajwar et al. | Diabetic effects of polyherbal formulation of Lawsonia inermis and Azadirachta indica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Airong Document name: Written notice of preliminary examination of application for patent for invention |
|
| C06 | Publication | ||
| PB01 | Publication | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Airong Document name: Notice of publication of application for patent for invention |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Cheng Hui Document name: Notification of registration of the invention patent right |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Patent director of Beijing xiandatong Technology Co., Ltd Document name: payment instructions |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Cheng Hui Document name: Notice of termination of patent right |
|
| DD01 | Delivery of document by public notice | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070718 Termination date: 20200817 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |